Antiviral profile of BILR 355 BS against a large panel of clinical isolates with mutations conferring resistance to currently available non-nucleoside reverse transcriptase inhibitors (NNRTI)

被引：0
|
作者：
Bonneau, PR
Robinson, PA
Lie, Y
Parkin, N
van Leeuwen, R
Bethell, R
机构：
[1] Boehringer Ingelheim Canada Ltd Res & Dev, Laval, PQ, Canada
[2] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
[3] Virolig Inc, San Francisco, CA USA
[4] Int Antiviral Therapy Evaluat Ctr, Amsterdam, Netherlands
来源：
ANTIVIRAL THERAPY | 2005年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 41 条
  • [1] Antiviral profile of BILR 355 BS against a large panel of clinical isolates with mutations conferring resistance to currently available non-nucleoside reverse transcriptase inhibitors (NNRTI)
    Bonneau, PR
    Robinson, PA
    Lie, Y
    Parkin, N
    van Leeuwen, R
    Bethell, R
    ANTIVIRAL THERAPY, 2005, 10 (04) : S81 - S81
  • [2] Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors
    Tombuyzer, Lotke
    Azijn, Hilde
    Rimsky, Laurence T.
    Vingerhoets, Johan
    Lecocq, Pierre
    Kraus, Guenter
    Picchio, Gaston
    de Bethune, Marie-Pierre
    ANTIVIRAL THERAPY, 2009, 14 (01) : 103 - 109
  • [3] Mutations in the reverse transcriptase connection and RNase H domains exhibit dual resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors
    Nikolenko, G. N.
    Delviks-Frankenberry, K. A.
    Jere, A.
    Pathak, V. K.
    ANTIVIRAL THERAPY, 2008, 13 (04) : A55 - A55
  • [4] Antiviral activity of TMC125, a potent next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), against >5000 recombinant clinical isolates exhibiting a wide range of NNRTI resistance
    Vingerhoets, J
    Van Marck, H
    Veldeman, J
    Peeters, M
    McKenna, P
    Pauwels, R
    de Béthune, MP
    ANTIVIRAL THERAPY, 2003, 8 (03) : U25 - U25
  • [5] Mutations at reverse transcriptase codon 103: phenotypic resistance to non-nucleoside reverse transcriptase inhibitor and clinical correlates
    Harrigan, PR
    Wynhoven, B
    Montaner, J
    McKenna, P
    Bacheler, L
    ANTIVIRAL THERAPY, 2003, 8 (03) : U104 - U105
  • [6] Q145M, a novel HIV-1 reverse transcriptase mutation conferring resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors
    Paolucci, S
    Baldanti, F
    Tinelli, M
    Labo, N
    Cattaneo, E
    Maga, G
    Gerna, G
    ANTIVIRAL THERAPY, 2002, 7 : S46 - S46
  • [7] Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors
    Saracino, A
    Monno, L
    Scudeller, L
    Cibelli, DC
    Tartaglia, A
    Punzi, G
    Torti, C
    Lo Caputo, S
    Mazotta, F
    Scotto, G
    Carosi, G
    Angarano, G
    JOURNAL OF MEDICAL VIROLOGY, 2006, 78 (01) : 9 - 17
  • [8] Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors
    Harrigan, PR
    Mo, T
    Wynhoven, B
    Hirsch, J
    Brumme, Z
    McKenna, P
    Pattery, T
    Vingerhoets, J
    Bacheler, LT
    AIDS, 2005, 19 (06) : 549 - 554
  • [9] Complexity of cross-resistance mutation patterns in diarylpyrimidine non-nucleoside reverse transcriptase inhibitors rilpivirine and etravirine in clinical isolates
    Matsuoka, K.
    Tanabe, F.
    Shigemi, U.
    Hattori, J.
    Ode, H.
    Masaoka, T.
    Morishita, R.
    Sawasaki, T.
    Yokomaku, Y.
    Iwatani, Y.
    Sugiura, W.
    ANTIVIRAL THERAPY, 2013, 18 : A110 - A110
  • [10] Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients
    Magiorkinis, E
    Paraskevis, D
    Lazanas, M
    Kiosses, VG
    Gargalianos, P
    Hatzakis, A
    AIDS, 1999, 13 (10) : 1276 - 1278
12345